Kiniksa Pharmaceuticals International plc Class A (KNSA)
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KNSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.38B
- P/E (TTM)
- 71.13
- Forward P/E
- 45.91
- EPS (TTM)
- $1.32
- Dividend yield
- None
- 52-week range
- 37.02 – 99.31
- Day range
- 92.68 – 95.29
- Volume / Avg
- 545.14K / 664.53K
- Beta
- —
- Shares outstanding
- 48.84M
52-week range
KNSA stock today
On Nov 20, KNSA ended the session at $93.90, adding $0.36 (0.38%), versus the S&P 500's 3.70% decline. Shares are 5.5% below their 52-week high of $99.31, set on Nov 9, 2026 and 153.6% above the 52-week low of $37.02, near the top of the past year's range. KNSA is up 127.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 125.8%.
At 71.1x trailing earnings, Kiniksa Pharmaceuticals International trades above the peer-group median of 47.8x. Its forward P/E of 45.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Kiniksa Pharmaceuticals International
Company profileKiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sanjiv K. Patel
- Headquarters
- London
- Employees
- 366
- IPO year
- 2018
- Website
- kiniksa.com
Financial highlights
Full financialsIn fiscal 2025, Kiniksa Pharmaceuticals International generated $677.6 million in revenue, up 60.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $59.0 million, for a net margin of 8.7% versus a median of -2.5% in the prior 5 years. Gross margin was 88.5% (up from 85.6%) and operating margin 11.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M |
| Growth | +60.09% | +56.60% | +22.74% | +471.24% | — |
| Net income | $59.01M | $-43.19M | $14.08M | $183.36M | $-157.92M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$111.57+18.82%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $0.56 vs $0.32
- Surprise
- +75.00%
KNSA news
All KNSA news- Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Kiniksa Pharmaceuticals International Average Price Target Raised 13.15% to $111.62Nasdaq
- Show Me The Money: The $100 Club Beckons For Kiniksa PharmaNasdaqKNSA, SUN
- Kiniksa (KNSA) Q3 2026 Earnings Call TranscriptNasdaq
- Kiniksa Pharmaceuticals, Ltd. Reports Q3 2026 Net Product Revenue of $286.0 millionNasdaq
- Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.56 beats by $0.21, revenue of $286M beats by $25.39MSeeking Alpha
- Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Kiniksa Pharmaceuticals International, plc Q3 2026 Earnings PreviewSeeking Alpha
Kiniksa Pharmaceuticals International peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs KNSA |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs KNSA |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs KNSA |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs KNSA |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs KNSA |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs KNSA |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs KNSA |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs KNSA |
Indexes, lists and sector
Kiniksa Pharmaceuticals International stock FAQ
What is Kiniksa Pharmaceuticals International's stock price today?
KNSA last traded at $93.90 as of Nov 20, 4:00 PM EST, up 0.38% on the day. Prices are delayed at least 15 minutes.
What is KNSA's P/E ratio?
KNSA trades at a trailing P/E ratio of 71.13 and a forward P/E of 45.91, compared with a median of 47.8 for its closest peers.
Who is Kiniksa Pharmaceuticals International's CEO?
Mr. Sanjiv K. Patel is the chief executive officer of Kiniksa Pharmaceuticals International plc Class A, which has about 366 employees.
What is the KNSA 52-week high?
The 52-week high for KNSA is $99.31 and the 52-week low is $37.02. The stock is currently 5.5% below its high.